CORRESP Filing
Inhibikase Therapeutics, Inc.
Date: June 25, 2025 · CIK: 0001750149 · Accession: 0001193125-25-146877
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288213
Letter
Re: Inhibikase Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed June 20, 2025 File No. 333-288213 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Inhibikase Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above- referenced registration statement (the “ Registration Statement ”) be accelerated to June 27, 2025, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Marishka DeToy at (617) 570-1926. If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926.
VIA EDGAR June 25, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549
Sincerely,
Inhibikase Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR June 25, 2025 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Inhibikase Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 Filed June 20, 2025 File No. 333-288213 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “ Act ”), Inhibikase Therapeutics, Inc. (the “ Company ”) hereby requests that the effective date of the above- referenced registration statement (the “ Registration Statement ”) be accelerated to June 27, 2025, at 4:01 pm Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our outside counsel, Goodwin Procter LLP, by calling Marishka DeToy at (617) 570-1926. If you have any questions regarding this request, please contact Marishka DeToy of Goodwin Procter LLP at (617) 570-1926. Sincerely, Inhibikase Therapeutics, Inc. /s/ David McIntyre David McIntyre Chief Financial Officer cc: Mark Iwicki, Inhibikase Therapeutics, Inc. Danielle Lauzon, Esq., Goodwin Procter LLP Marishka DeToy, Esq., Goodwin Procter LLP